iShares MSCI Taiwan ETF vs Merck & Co., Inc. — how do they compare? iShares MSCI Taiwan ETF trades at $106.23, while Merck & Co., Inc. trades at $132.67 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while iShares MSCI Taiwan ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares MSCI Taiwan ETF nearer its low. Which is the better fit depends on your goals.
| EWT | MRK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $111.53 | $131.84 |
52-Week Low | $58.05 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Signals from Pluang's Aura AI — not financial advice
EWT, the iShares MSCI Taiwan ETF, trades at $106.50, up 4.23% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF is heavily concentrated in Taiwan's technology sector, particularly semiconductors like TSMC, benefiting from AI-driven demand. Recent news highlights strong performance in 2026, with gains near 50%, though foreign outflows in July indicate some rotation away from AI-heavy markets.
Outlook remains positive due to Taiwan's critical role in AI semiconductor supply chains, but risks include geopolitical tensions with China, market concentration, and volatility from foreign capital flows. Analyst sentiment is generally bullish, citing growth-adjusted valuations and resilient fundamentals.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Trailing returns across standard periods
Latest headlines on both assets
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →